Cite
Regression of human prostate cancer xenografts in mice by AMG 212/BAY2010112, a novel PSMA/CD3-Bispecific BiTE antibody cross-reactive with non-human primate antigens.
MLA
Friedrich, Matthias, et al. “Regression of Human Prostate Cancer Xenografts in Mice by AMG 212/BAY2010112, a Novel PSMA/CD3-Bispecific BiTE Antibody Cross-Reactive with Non-Human Primate Antigens.” Molecular Cancer Therapeutics, vol. 11, no. 12, Dec. 2012, pp. 2664–73. EBSCOhost, https://doi.org/10.1158/1535-7163.MCT-12-0042.
APA
Friedrich, M., Raum, T., Lutterbuese, R., Voelkel, M., Deegen, P., Rau, D., Kischel, R., Hoffmann, P., Brandl, C., Schuhmacher, J., Mueller, P., Finnern, R., Fuergut, M., Zopf, D., Slootstra, J. W., Baeuerle, P. A., Rattel, B., & Kufer, P. (2012). Regression of human prostate cancer xenografts in mice by AMG 212/BAY2010112, a novel PSMA/CD3-Bispecific BiTE antibody cross-reactive with non-human primate antigens. Molecular Cancer Therapeutics, 11(12), 2664–2673. https://doi.org/10.1158/1535-7163.MCT-12-0042
Chicago
Friedrich, Matthias, Tobias Raum, Ralf Lutterbuese, Markus Voelkel, Petra Deegen, Doris Rau, Roman Kischel, et al. 2012. “Regression of Human Prostate Cancer Xenografts in Mice by AMG 212/BAY2010112, a Novel PSMA/CD3-Bispecific BiTE Antibody Cross-Reactive with Non-Human Primate Antigens.” Molecular Cancer Therapeutics 11 (12): 2664–73. doi:10.1158/1535-7163.MCT-12-0042.